Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06942442 · ClinicalTrials.gov registry record · Phase 2

A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma

A Phase 2 study of HLA-A*0201 Positive Cells Present and Clear Cell Sarcoma (CCS), sponsored by Sarcoma Alliance for Research through Collaboration.

Recruiting
Registry status
Phase 2
Development phase
47
Enrollment target
2
Study locations

NCT06942442 is a Phase 2 study of HLA-A*0201 Positive Cells Present and Clear Cell Sarcoma (CCS) that is actively recruiting participants, run by Sarcoma Alliance for Research through Collaboration. The registered enrollment target is 47 participants. The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06942442, a Phase 2 study of HLA-A*0201 Positive Cells Present and Clear Cell Sarcoma (CCS), is actively recruiting participants, sponsored by Sarcoma Alliance for Research through Collaboration.

RECRUITING
Registry status
Phase 2
Development phase
47 participants
Enrollment target
2
Study locations

Study Summary

This is a multi-center, open label, phase II study of tebentafusp in patients with unresectable or metastatic clear cell sarcoma (CCS).

Interventions

  • DRUG Tebentafusp
  • DRUG Physician's Choice

Study Locations (2)

California

  • University of Southern California - Norris Cancer Center - Los Angeles

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 47 participants
Start Date 2025-10-22
Est. Completion 2030-10-01
Phase Phase 2

What the Registry Record Tells You About NCT06942442

The ClinicalTrials.gov registry entry for NCT06942442 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sarcoma Alliance for Research through Collaboration, which has 20 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with HLA-A*0201 Positive Cells Present appearing as the primary indexed condition, and to 2 interventions - of which Tebentafusp is the first listed.

NCT06942442 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, New York.

Frequently Asked Questions

What is clinical trial NCT06942442 about?

NCT06942442 is a clinical study titled "A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma". This is a multi-center, open label, phase II study of tebentafusp in patients with unresectable or metastatic clear cell sarcoma (CCS).

What is the current status of trial NCT06942442?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2025-10-22. Estimated completion is 2030-10-01.

What conditions does trial NCT06942442 study?

This clinical trial studies the following conditions: HLA-A*0201 Positive Cells Present, Clear Cell Sarcoma (CCS).

What interventions are being tested in trial NCT06942442?

The interventions under investigation include: Tebentafusp (DRUG), Physician's Choice (DRUG).

Who is sponsoring clinical trial NCT06942442?

This trial is sponsored by Sarcoma Alliance for Research through Collaboration, which has 20 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06942442 being conducted?

This trial has 2 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HLA-A*0201 Positive Cells Present

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.